We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Limits Controlled Correspondence Options for Generic Drugmakers
FDA Limits Controlled Correspondence Options for Generic Drugmakers
A final guidance published Dec. 17 indicates the FDA will limit the kinds of questions generic drug sponsors may submit to the agency to get feedback during drug development.